PDP-AMANTADINE HYDROCHLORIDE CAPSULES

Država: Kanada

Jezik: angleščina

Source: Health Canada

Aktivna sestavina:

AMANTADINE HYDROCHLORIDE

Dostopno od:

PENDOPHARM DIVISION OF PHARMASCIENCE INC

Koda artikla:

N04BB01

INN (mednarodno ime):

AMANTADINE

Odmerek:

100MG

Farmacevtska oblika:

CAPSULE

Sestava:

AMANTADINE HYDROCHLORIDE 100MG

Pot uporabe:

ORAL

Enote v paketu:

100

Tip zastaranja:

Prescription

Terapevtsko območje:

ADAMANTANES

Povzetek izdelek:

Active ingredient group (AIG) number: 0109101001; AHFS:

Status dovoljenje:

APPROVED

Datum dovoljenje:

2017-03-13

Lastnosti izdelka

_ _
pdp-AMANTADINE HYDROCHLORIDE
_ _
_Page 1 of 42 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
PDP-AMANTADINE HYDROCHLORIDE CAPSULES
amantadine hydrochloride capsules
100 mg
House Standard
PR
PDP-AMANTADINE HYDROCHLORIDE SYRUP
amantadine hydrochloride oral solution
10 mg/mL
USP
Antiparkinsonian Agent
Antiviral Agent
PENDOPHARM, Division of Pharmascience Inc.
6111 Royalmount Avenue, Suite 100
Montréal, QC, Canada
H4P 2T4
Date of Initial Authorization:
Jun 27, 1992
Date of Revision:
Jun 13, 2022
Submission Control Number: 261229
_ _
_ _
_pdp-AMANTADINE HYDROCHLORIDE_
_ _
_Page 2 of 42 _
RECENT MAJOR LABEL CHANGES
1 Indications
12/2021
2 Contraindications
06/2022
4 Dosage and Administration
12/2021
4.2 Recommended Dose and Dosage Adjustment
06/2022
7 Warnings and Precautions
12/2021
7 Warnings and Precautions, Cardiovascular
06/2022
7 Warnings and Precautions, Neurologic
06/2022
7 Warnings and Precautions, Ophthalmologic
06/2022
7 Warnings and Precautions, Psychiatric
06/2022
7 Warnings and Precautions, Renal
06/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics...........................................................................................................
5
2
CONTRAINDICATIONS
.................................................................................................
5
4
DOSAGE AND
ADMINISTRATION